Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.

Nature cell biology - 1 Sept 2018

Nichols Robert J, Haderk Franziska, Stahlhut Carlos, Schulze Christopher J, Hemmati Golzar, Wildes David, Tzitzilonis Christos, Mordec Kasia, Marquez Abby, Romero Jason, Hsieh Tientien, Zaman Aubhishek, Olivas Victor, McCoach Caroline, Blakely Collin M, Wang Zhengping, Kiss Gert, Koltun Elena S, Gill Adrian L, Singh Mallika, Goldsmith Mark A, Smith Jacqueline A M, Bivona Trever G

Abstract excerpt

Oncogenic alterations in the RAS/RAF/MEK/ERK pathway drive the growth of a wide spectrum of cancers. While BRAF and MEK inhibitors are efficacious against BRAFV600E-driven cancers, effective targeted therapies are lacking for most cancers driven by other pathway alterations, including non-V600E oncogenic BRAF, RAS GTPase-activating protein (GAP) NF1 (neurofibromin 1) loss and oncogenic KRAS. Here, we show that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Extracellular Signal-Regulated MAP Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Guanosine Triphosphate

Share to Mitogen-Activated Protein Kinase Kinases

Share to Neurofibromin 1

Share to Protein Tyrosine Phosphatase, Non-Receptor Type 11

Share to raf Kinases

Share to SOS1 Protein

Share to Tumor Burden

Source

Open in PubMed Open full text

Identifiers

PMID: 30104724
DOI: 10.1038/s41556-018-0169-1
PMCID: PMC6115280

Genes

BRAF
KRAS
PTPN11
SOS1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.PMID 30104724Read ↗

Inhibition of SHP2 as an approach to block RAS-driven cancers.Semantic proximity Read ↗

Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesisSemantic proximity Read ↗

Dual inhibition of SHP2 and autophagy suppresses NF1-associated Malignant Peripheral Nerve Sheath TumorsSemantic proximity Read ↗

SHP2 clinical phenotype, cancer, or RASopathies, can be predicted by mutant conformational propensities.Semantic proximity Read ↗

Targeting SHP2 phosphatase in hematological malignancies.Semantic proximity Read ↗

Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.Semantic proximity Read ↗

Off-target autophagy inhibition by SHP2 allosteric inhibitors contributes to their antitumor activity in RAS-driven cancersSemantic proximity Read ↗

Targeted degradation of the oncogenic phosphatase SHP2Semantic proximity Read ↗

PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer.Semantic proximity Read ↗

Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application.Semantic proximity Read ↗

Targeting PDGFRA-SHP2 signaling enhances radiotherapy in IDH1-mutant glioma.Semantic proximity Read ↗

Targeted Degradation of the Oncogenic Phosphatase SHP2.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.